Advertisement
Screener

AIM IMMUNOTECH INC. (AIM) Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)

2.8 / 5 stars · 68/120 Roast Me

AIM IMMUNOTECH INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)

AIM IMMUNOTECH INC. (AIM) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) of -$826.00 thousand for the 9-month period ending 2018-09-30, per its 10-Q filed 2018-11-14.

Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation

us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease · last filed 2018-11-14

  • AIM IMMUNOTECH INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2018-09-30 was -$695.00K.
  • AIM IMMUNOTECH INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2018-06-30 was -$362.00K, a 127.51% decline year-over-year.
  • AIM IMMUNOTECH INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2018-03-31 was $231.00K.
  • AIM IMMUNOTECH INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2017-12-31 was -$32.00K.
  • AIM IMMUNOTECH INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for fiscal 2017 was -$2.42M.
  • AIM IMMUNOTECH INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for fiscal 2016 was -$1.68M.
Period endFair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 3 monthFair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 6 monthFair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 9 monthFair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 12 month
2018-09-30-$695.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14
-$1.06M
derived: sum of 2 quarters · filed 2018-11-14
-$826.00K
10-Q · filed 2018-11-14
-$858.00K
derived: sum of 4 quarters · filed 2018-11-14
2018-06-30-$362.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-14
-$131.00K
10-Q · filed 2018-08-14
-$163.00K
derived: sum of 3 quarters · filed 2018-08-14
-$3.47M
derived: sum of 4 quarters · filed 2018-08-14
2018-03-31$231.00K
10-Q · filed 2018-05-15
$199.00K
derived: sum of 2 quarters · filed 2018-05-15
-$3.11M
derived: sum of 3 quarters · filed 2018-05-15
-$1.79M
derived: sum of 4 quarters · filed 2018-05-15
2017-12-31-$32.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-30
-$3.34M
derived: sum of 2 quarters · filed 2018-03-30
-$2.02M
derived: sum of 3 quarters · filed 2018-03-30
-$2.42M
10-K · filed 2018-03-30
2017-09-30-$3.31M
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-14
-$1.99M
derived: sum of 2 quarters · filed 2017-11-14
-$2.38M
10-Q · filed 2017-11-14
-$3.96M
derived: sum of 4 quarters · filed 2017-11-14
2017-06-30$1.32M
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14
$923.00K
10-Q · filed 2017-08-14
-$651.00K
derived: sum of 3 quarters · filed 2017-08-14
2017-03-31-$393.00K
10-Q · filed 2017-05-15
-$1.97M
derived: sum of 2 quarters · filed 2017-05-15
2016-12-31-$1.57M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-31
-$1.68M
10-K · filed 2017-03-31
2016-09-30-$103.00K
10-Q · filed 2016-11-14

Similar stocks

Stock NameCountryMarket CapPE Ratio
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ)United States$0.006B
CERO THERAPEUTICS HOLDINGS, INC. (CERO)United States$0.007B
PharmaCyte Biotech, Inc. (PMCB)United States$0.005B
TScan Therapeutics, Inc. (TCRX)United States$0.008B-1.23
WINDTREE THERAPEUTICS INC /DE/ (WINT)United States$0.003B-0.32
VivoSim Labs, INC. (VIVS)United States$0.003B
Calidi Biotherapeutics, Inc. (CLDI)United States$0.003B
CURIS INC (CRIS)United States$0.002B-0.05
Senti Biosciences Holdings, Inc. (SNTI)United States$0.011B-0.70
Silexion Therapeutics Corp (SLXN)$0.001B